登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688630 证券简称：芯碁微装 公告编号：2026-001 合肥芯碁微电子装备股份有限公司 关于控股股东、实际控制人及其一致行动人权益变动触及5%整数倍的提示性公告 合肥芯碁微电子装备股份有限公司控股股东、实际控制人程卓女士及其一致行动人保证向保证本公司提 供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 ■ 3.一致行动人信息 ■ 二、权益变动触及1%刻度的基本情况 4、截至本公告披露日，公司控股股东、实际控制人减持计划尚未实施完毕，公司及股东将继续严格遵 守减持相关规定，及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 合肥芯碁微电子装备股份有限公司 2026年1月8日 合肥芯碁微电子装备股份有限公司 公司于2026年1月7日收到控股股东、实际控制人、董事长程卓女士出具的《关于权益变动触及5%整数 倍的告知函》，程卓女士于2025年12月17日至 ...

福立旺(688678.SH)发布公告，因自身资金需求，公司控股股东WINWIN计划通过集中竞价交易方式和 大宗交易方式减持公司股份数量合计不超过780万股，即不超过公司总股本的2.9977%。 ...

公告强调，截至目前，本次交易项下股权未交割，蓝芯合伙未支付股权转让价款。终止交易是基于公司 自身情况和上海星思半导体现状，旨在控制投入、减少对外投资对公司的影响，维护公司及全体股东尤 其是中小股东的利益。 蓝盾光电于2020年8月登陆创业板，主营业务为高端分析测量仪器的研制、生产、软件开发、数据应用 及服务，产品和服务主要用于环境监测、气象观测等领域；而成立于2020年的上海星思半导体，相关芯 片主要应用于5G CPE、卫星智能手机原型机、低轨卫星通信终端、卫星物联终端、卫星联测终端等产 品，双方主营业务相关性较弱。 蓝盾光电与上海星思半导体的关联可以追溯至2023年。2023年12月29日，蓝盾光电宣布以1.8亿元自有 资金参与上海星思半导体的新一轮融资，预计取得约5%的股权。按相应比例换算，上海星思半导体投 后估值约为36亿元，增值率高达5142.86%。而2022年和2023年前三季度，上海星思半导体却连续亏 损，合计亏损超过8亿元。 这项高溢价的跨界投资随即引来交易所关注。 2024年1月2日，深交所向蓝盾光电下发关注函，要求说明该项融资的筹划过程、关键决策环节及参与人 员，并要求核查公司董监高、持股 ...

据蓝盾光电公告，公司及其控制的蓝芯合伙经与交易对方珠海洛恒协商，拟终止关于上海星思半导体的《股权转让协议》并签署正式终止协议。 公告强调，截至目前，本次交易项下股权未交割，蓝芯合伙未支付股权转让价款。终止交易是基于公司自身情况和上海星思半导体现状，旨在控制投入、 减少对外投资对公司的影响，维护公司及全体股东尤其是中小股东的利益。 △图源：图虫 而在交易停滞期间，蓝盾光电控股股东及一致行动人多次减持。 △图源：图虫 蓝盾光电于2020年8月登陆创业板，主营业务为高端分析测量仪器的研制、生产、软件开发、数据应用及服务，产品和服务主要用于环境监测、气象观测 等领域；而成立于2020年的上海星思半导体，相关芯片主要应用于5G CPE、卫星智能手机原型机、低轨卫星通信终端、卫星物联终端、卫星联测终端等 产品，双方主营业务相关性较弱。 蓝盾光电与上海星思半导体的关联可以追溯至2023年。2023年12月29日，蓝盾光电宣布以1.8亿元自有资金参与上海星思半导体的新一轮融资，预计取得 约5%的股权。按相应比例换算，上海星思半导体投后估值约为36亿元，增值率高达5142.86%。而2022年和2023年前三季度，上海星思半导 ...

Core Viewpoint - The major shareholder of HeFu China plans to reduce its stake by up to 2%, which has led to a significant drop in the company's stock price following a period of rapid increase [1][5][6]. Group 1: Shareholder Actions - HeFu (Hong Kong) Holdings Limited, the controlling shareholder, intends to sell up to 796.11 million shares, representing 2% of the total share capital, through block trades and centralized bidding [5]. - The planned reduction is motivated by the need to enhance operational funds for projects, including the development of a magnetic resonance imaging navigation radiation therapy system [5][6]. Group 2: Stock Performance - Following the announcement of the reduction plan, HeFu China's stock price fell by 10.02% on December 3, closing at 23 CNY per share after opening at 24 CNY [4][5]. - The stock had previously surged by 244.31% from October 28 to December 3, despite multiple risk warnings and trading suspensions [6]. Group 3: Financial Performance - HeFu China reported a net profit of approximately -12.39 million CNY for the first three quarters of the year, indicating a shift from profit to loss, with a revenue decline of 22.8% year-on-year [7]. - The company’s revenue projections for 2022 to 2024 are 1.28 billion CNY, 1.093 billion CNY, and 939 million CNY, with corresponding net profits of approximately 82.72 million CNY, 47.19 million CNY, and 27.57 million CNY [7].

Core Viewpoint - The major shareholder of HeFu China, HeFu (Hong Kong) Holdings Limited, plans to reduce its stake by up to 2% amid a significant stock price increase, which has raised concerns among investors about potential market manipulation and the company's underlying fundamentals [1][3][4]. Group 1: Shareholder Actions - HeFu (Hong Kong) intends to reduce its holdings by a total of 7,961,100 shares, representing 2% of the company's total share capital, through block trades and centralized bidding [3]. - The planned reduction is motivated by the need to enhance operational funds, including financing for a magnetic resonance imaging navigation radiation therapy system project [3][4]. - Following the announcement, HeFu China's stock price dropped to its daily limit, closing at 23 CNY per share, a decrease of 10.02% on December 3 [3]. Group 2: Stock Performance - Since October 28, HeFu China's stock price has surged by 244.31%, despite multiple risk warnings and trading suspensions [3][5]. - The stock's market value increased by approximately 3.573 billion CNY during this period, while the value of the shares intended for reduction is about 183 million CNY [4]. Group 3: Financial Performance - HeFu China reported a net profit loss of approximately 12.39 million CNY for the first three quarters of the year, a significant decline compared to the previous year [5]. - Revenue for the same period was 549 million CNY, reflecting a year-on-year decrease of 22.8% due to changes in the macroeconomic environment and price reductions in the medical industry [5]. - The company anticipates further revenue declines in the coming years, projecting revenues of approximately 1.28 billion CNY, 1.093 billion CNY, and 939 million CNY for 2022, 2023, and 2024, respectively [5].

Core Insights - The recent announcements from Hexing Packaging include the complete sale of the first employee stock ownership plan after ten years and a plan by the controlling shareholder to reduce their stake by up to 1.91% [1][2] - Following the announcement of the shareholder's reduction plan, Hexing Packaging's stock price surged to a five-year high of 4.08 yuan, contrasting sharply with the losses from the employee stock ownership plan [1][2] Shareholder Reduction Plan - The controlling shareholder, Xinjiang Xinghui Ju Equity Investment Management Partnership, plans to reduce their holdings by up to 23.22 million shares, representing 1.91% of the total share capital, from December 4, 2025, to March 3, 2026 [1][2] - As of now, Xinjiang Xinghui Ju holds 397 million shares, accounting for 32.73% of the total share capital [1] Employee Stock Ownership Plan - The first phase of the employee stock ownership plan has been fully sold, with a total of 12.48 million shares sold, representing 1.03% of the total share capital [2][5] - The employee stock ownership plan began in July 2015 and has undergone six extensions, with the last extension approved in May 2025 [2][3] Financial Performance - The stock price of Hexing Packaging reached a low of 1.87 yuan in 2024 and has since risen to 4.08 yuan by November 13, 2025, marking a significant recovery [2] - The employee stock ownership plan incurred losses, with the total sale amounting to approximately 45.93 million yuan based on a closing price of 3.68 yuan prior to the sale [5] - Over the ten years, Hexing Packaging has distributed more than 1.2 billion yuan in dividends, with the employee stock ownership plan receiving over 12 million yuan in cash dividends [5] Share Pledge Status - Currently, 19.08% of the controlling shareholder's shares are under pledge, with a total of 75.79 million shares pledged, representing 6.25% of the company's total share capital [5]

Core Viewpoint - The controlling shareholder of the company, Haodangjia Group, plans to reduce its stake in the company by up to 2.7% of the total share capital, equating to a maximum of 39,446,846 shares within a specified timeframe [1] Summary by Relevant Sections - **Share Reduction Plan** - Haodangjia Group intends to reduce its holdings through centralized bidding and block trading methods [1] - The reduction will not exceed 2.7% of the company's total share capital, which translates to a maximum of 39,446,846 shares [1] - **Adjustment Clause** - If any corporate actions such as dividend distribution, bonus shares, capital reserve conversion, new share issuance, or rights issues occur during the reduction period, the number of shares to be reduced will be adjusted accordingly [1]

Core Viewpoint - The company Changjie Tong (01588.HK) announced that its controlling shareholder, Yongyou Network Technology Co., Ltd. (stock code: 600588), will sell a total of 42,107,849 H-shares through block trading, which represents approximately 12.93% of the company's issued shares as of the announcement date [1] Summary by Relevant Sections - **Share Sale Details** - Yongyou and its subsidiary, Yongyou Youpu Information Technology Co., Ltd., will sell 28,135,071 shares and 13,972,778 shares respectively, at a price of HKD 7.60 per share [1] - The shares sold represent about 8.64% and 4.29% of the company's issued shares, excluding treasury shares [1] - **Post-Sale Ownership** - After the sale, Yongyou will continue to hold 174,350,542 shares in the company, which accounts for approximately 53.53% of the issued shares [1] - This includes 173,344,366 shares directly held by Yongyou and 1,006,176 shares held by its subsidiary, Beijing Yongyou Happiness Investment Management Co., Ltd. [1] - **Strategic Implications** - The controlling shareholder expresses confidence in the company's business operations [1] - The sale is intended to deepen connections with long-term value investors, broaden the shareholder base, and enhance the liquidity of the company's stock [1]

Group 1 - The stock price of Boji Pharmaceutical closed at 11.98 yuan on August 21, 2025, down 3.07% from the previous trading day, with a trading volume of 567 million yuan and a turnover rate of 16.61% [1] - Boji Pharmaceutical operates in the healthcare services industry, with 99.39% of its revenue coming from service-related activities as reported in the 2024 financial report [1] - The controlling shareholder Wang Tingchun and his concerted parties plan to reduce their holdings by no more than 11.4865 million shares, accounting for 3% of the total share capital, due to personal funding needs [1] Group 2 - On August 21, the net outflow of main funds was 18.1492 million yuan, but over the past five days, the overall net inflow of main funds was 139 million yuan [1]